Venture Capital News: Artera Launches With $90M
2023-03-21
SAN FRANCISCO, CA, Artera, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, launches publicly today with $90 million in funding.
The investment comes from a syndicate of prominent tech and healthcare investors, comprised of seven institutions (Coatue, Johnson & Johnson Innovation - JJDC, Inc., Koch Disruptive Technologies, Walden Catalyst Ventures, TIME Ventures, Breyer Capital, The Factory) and 11 angel investors (Marc Benioff, Jim Breyer, Lip-Bu Tan, Chris Re, Andy Jacques, Amarjit Gill, Jeff Dean, Steve Blank, Dennis Wong, Clarence So, Michael Driscoll).
Artera is a leading precision medicine company developing AI tests to personalize therapy for cancer patients. Their test provides risk stratification and prediction of therapeutic benefit, including the first-ever predictive test for localized prostate cancer.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors